Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed\* colorectal cancer~  * Metastatic disease~ * The site of the primary tumor must have been confirmed endoscopically, radiologically, or surgically to be the colon or rectum NOTE: \*Confirmation is not required for recurrent metastatic disease unless an interval of \> 5 years has elapsed between the initial primary surgery and the development of metastases~* Measurable disease~  * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan~* No CNS metastases~PATIENT CHARACTERISTICS:~Age~* 18 to 80~Performance status~* ECOG 0-1~Life expectancy~* More than 3 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL (transfusion allowed)~Hepatic~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Bilirubin ≤ ULN~* No unstable or uncompensated hepatic disease~Renal~* Creatinine \< 1.5 times ULN OR~* Creatinine clearance \> 60 mL/min~* No unstable or uncompensated renal disease~Cardiovascular~* No unstable or uncompensated cardiac disease~Pulmonary~* No evidence of clinically active interstitial lung disease~  * Asymptomatic patients with chronic stable radiographic changes are eligible~* No unstable or uncompensated respiratory disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after study participation~* No known hypersensitivity to gefitinib or any of its excipients~* No known hypersensitivity to platinum compounds, fluorouracil, or capecitabine~* No severe or uncontrolled systemic disease~* Able to receive oral medication~* No known dihydropyrimidine dehydrogenase (DPD) deficiency~* No known peripheral neuropathy ≥ grade 1~  * Absence of deep tendon reflexes as the sole neurological abnormality allowed~* No other significant clinical disorder or laboratory finding that would preclude study participation~* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix (phase II only)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 4 weeks since prior chemotherapy for metastatic colorectal cancer (phase I)~* No prior chemotherapy for metastatic disease (phase II)~  * Prior fluorouracil and leucovorin calcium in the adjuvant setting allowed provided the last treatment was administered more than 6 months before the development of metastatic disease~* No prior irinotecan and oxaliplatin (phase II)~Endocrine therapy~* Not specified~Radiotherapy~* No concurrent radiotherapy for colorectal cancer~Surgery~* See Disease Characteristics~* More than 4 weeks since prior major surgery (e.g., laparotomy)~Other~* Recovered from all prior therapy (no unresolved chronic toxicity \> grade 2)~* More than 4 weeks since prior investigational drugs~* No prior epidermal growth factor receptor inhibitor therapy (phase II)~* No concurrent phenytoin, carbamazepine, rifampin, barbiturates, or Hypericum perforatum (St. John's wort)~* No other concurrent investigational drugs~* No other concurrent systemic therapy for colorectal cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues